

<sup>1</sup>For consistency this report follows format used by the U.S. National Newborn Screening & Genetics Resource Center

A dot "●" indicates that universal screening for the condition is required by law

**A** = universally offered but not yet required, **B** = offered to select populations or by request, **C** = testing required or offered universally but not yet implemented, **D** = likely to be detected (and reported) as a by-product of MRM screening (MS/MS) targeted by law

For questions or comments about this report, contact John Adams at [john.adams7@sympatico.ca](mailto:john.adams7@sympatico.ca)

Province/Territory (east to west/ west to east)	Core <sup>1</sup> Conditions:									Additional Conditions Included (universally offered unless otherwise indicated)
	Hearing	Endocrine		Hemoglobin (HB)			Other			
	HEAR	CH	CAH	S/S	S/C	S/A	BIO	GALT	CF	
Newfoundland & Labrador		A								
Prince Edward Island	A	A								Covered by NBS Lab in Nova Scotia
Nova Scotia		A								HB pilot under consideration; discussing CF
New Brunswick	A	A								
Quebec	B	A								Expansion under review; second screen by urine collected by parent at newborn Day 21 – 90% participation: 12 conditions of amino, urea cycle & organic acids plus 11 transport disorders of amino acids (Fanconi syndrome, Cystinurias, Hartnup syndrome, Cystathioninemia, Prolidase deficiency, etc.)
Ontario	A	A	A	A	A	A	A	A	C <sup>1</sup>	Expanding from 3 to 29 disorders; C <sup>1</sup> = to be universally offered by end 2007 = ACMG core panel
Manitoba	B	A	A				A	A		Under review; plan to add MS/MS in 2007 targeted screening for GA1 (Oji-Cree), CPT1 (Hutterites) and Duchenne Muscular Dystrophy
Saskatchewan	B	●	C				C	B/C	C	
Alberta	B	A	A				A		A	Pilot for universal hearing screening in 4 regions (Calgary, Chinook, Mistahia & Palliser)
British Columbia	C	A						A		Expansion under review; universal hearing screening by end 2008
Yukon	A	A						A		Covered by NBS lab in British Columbia
Northwest Territories	B	A					A		A	Covered by NBS lab in Alberta
Nunavut - Kitimeot region		A					A		A	Covered by NBS lab in Alberta
Nunavut - Kivalliq region	B	A	A				A	A		Covered by NBS lab in Manitoba
Nunavut - Baffin region	B	A								Covered by NBS labs in Quebec; Second screen by urine sample at newborn Day 21 – 23 conditions

### Deficiency/Disorder Abbreviations and Names

<b>BIO</b>	Biotinidase	<b>CF</b>	Cystic fibrosis	<b>GALT</b>	Transferase deficient galactosemia (Classical)	<b>HB S/C</b>	Sickle – C disease	<b>HEAR</b>	Hearing screening
<b>CAH</b>	Congenital adrenal hyperplasia	<b>CH</b>	Congenital hyperthyroidism	<b>HB S/S</b>	Sickle cell disease	<b>HB S/A</b>	S-βeta thalassemia		

### Other Disorders

<b>5-OXO</b>	5-oxoprolinuria (pyroglutamic aciduria)	<b>G6PD</b>	Glucose 6 phosphate dehydrogenase	<b>NKH</b>	Nonketotic hyperglycinemia
<b>CPS</b>	Carbamoylphosphate synthetase	<b>HHH</b>	Hyperammonemia/ornithinemia/ citrullinemia (Ornithine transporter defect)	<b>OTC</b>	Ornithine transcarbamylase
<b>EMA</b>	Ethylmalonic encephalopathy	<b>HIV</b>	Human immunodeficiency virus	<b>TOXO</b>	Toxoplasmosis

A dot "●" indicates that screening for the condition is universally required by Law  
**A** = universally offered but not yet required, **B** = offered to select populations or by request, **C** = testing required or offered universally but not yet implemented, **D** = likely to be detected (and reported) as a by-product of MRM screening (MS/MS) targeted by Law

For questions or comments about this report, contact John Adams at [john.adams7@sympatico.ca](mailto:john.adams7@sympatico.ca)

Province/Territory (east to west/ west to east)	Core <sup>1</sup> Conditions: Metabolic																			
	Fatty Acid Disorders					Organic Acid Disorders								Amino Acid Disorders						
	CUD	LCHAD	MCAD	TFP	VLCAD	GA-I	HMG	IVA	3-MCC	Cbl-A,B	BKT	MUT	PROP	MCD	ASA	CIT	HCY	MSUD	PKU	TYR-I
<b>Newfoundland &amp; Labrador</b>			A														A		A	A
<b>Prince Edward Island</b>	A	A	A	A	A	A		A										A	A	
<b>Nova Scotia</b>	A	A	A	A	A	A		A										A	A	
<b>New Brunswick:</b>	A	A	A	A	A	A		A										A	A	
<b>Quebec</b>						A	A	A	A	A		A			A	A			A	A
<b>Ontario</b>	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A
<b>Manitoba</b>						B													A	
<b>Saskatchewan</b>	B	A	A	A	A	A	A	A	A	A	A	A	A	A	B	A	B	A	●	A
<b>Alberta</b>	A	A	A	A	A	A	A	A	A			A			A	A	A	A	A	A
<b>British Columbia</b>			A																A	
<b>Yukon</b>			A																A	
<b>Northwest Territories</b>	A	A	A	A	A	A	A	A	A				A			A	A	A	A	A
<b>Nunavut - Kitmeot region</b>	A	A	A	A	A	A	A	A	A				A			A	A	A	A	A
<b>Nunavut - Kivalliq region</b>						B													A	
<b>Nunavut - Baffin region</b>						A	A	A	A		A			A	A				A	A

<sup>1</sup>Terminology consistent with American College of Medical Genetics report - Newborn Screening: Toward a Uniform Screening Panel and System 2005, p. 63.

**Deficiency/Disorder Abbreviations and Names (optional nomenclature)**

<b>3-MCC</b>	3-Methylcrotonyl-CoA carboxylase	<b>CUD</b>	Carnitine uptake defect (Carnitine transport defect)	<b>LCHAD</b>	Long-chain hydroxyacyl-CoA dehydrogenase	<b>PKU</b>	Phenylketonuria/hyperphenylalaninemia
<b>ASA</b>	Argininosuccinate acidemia	<b>GA-1</b>	Glutaric acidemia type 1	<b>MCAD</b>	Medium-chain acyl-CoA dehydrogenase	<b>PROP</b>	Propionic acidemia (Propionyl-CoA carboxylase)
<b>BKT</b>	Beta ketothiolase (mitochondrial acetoacetyl-CoA thiolase ; short-chain ketoacyl thiolase; T2)	<b>HCY</b>	Homocystinuria (cystathionine beta synthase)	<b>MCD</b>	Multiple carboxylase (Holocarboxylase synthetase )	<b>TFP</b>	Trifunctional protein
<b>CBL A,B</b>	Methylmalonic acidemia (Vitamin B12 Disorders)	<b>HMG</b>	3-Hydroxy 3 -methylglutaric aciduria (3-Hydrox 3-methylglutaryl-CoA lyase )	<b>MSUD</b>	Maple syrup urine disease (branched-chain ketoacid dehydrogenase )	<b>TYR-1</b>	Tyrosinemia Type 1
<b>CIT I</b>	Citrullinemia type I (Argininosuccinate synthetase)	<b>IVA</b>	Isovaleric acidemia (Isovaleryl-CoA dehydrogenase )	<b>MUT</b>	Methylmalonic Acidemia (methylmalonyl-CoA mutase)	<b>VLCAD</b>	Very long-chain acyl-CoA dehydrogenase

A dot "●" indicates that screening for the condition is universally required by Law

**A** = universally offered but not yet required, **B** = offered to select populations, or by request, **C** = testing required or offered universally but not yet implemented, **D** = likely to be detected (and reported) as a by-product of MRM screening (MS/MS) targeted by Law

For questions or comments about this report, contact John Adams at [john.adams7@sympatico.ca](mailto:john.adams7@sympatico.ca)

Province/ Territory (east to west; west to east)	Secondary Target <sup>1</sup> Conditions																									
	Fatty Acid Disorders							Organic Acid Disorders						Amino Acid Disorders						Other Metabolic		Hbg				
	CACT	CPT-Ia	CPT- II	DE-RED.	GA-II	MCKAT	M/SCHAD	SCAD	2M3HBA	2MBG	3MGA	Cbl-C,D	IBG	MAL	ARG	BIOPT-BS	BIOPT-REG	CIT-II	H-PHE	MET	TYR- II	TYR- III	GALE	GALK	Variant hemoglobins	
Nfld. & Labrador																										
Prince Edward Island	A	A	A		A																					
Nova Scotia	A	A	A		A																					
New Brunswick	A	A	A		A																					
Quebec												A			A			A								
Ontario																										
Manitoba		B																								
Sask.		A	A	B	A	A	A	A	A	A	A	A	A	A	B	B	A	A	A	A	A	A	B	B	B	B
Alberta																										
British Columbia																										
Yukon																										
Northwest Territories																										
Nunavut - Kitimeot																										
Nunavut - Kivalliq																										
Nunavut - Baffin												A			A			A								

<sup>1</sup>Terminology consistent with American College of Medical Genetics report - Newborn Screening: Toward a Uniform Screening Panel and System 2005, p. 63.

**Deficiency/Disorder Abbreviations and Names (optional names)**

<b>2M3HBA</b>	2-Methyl-3-hydroxy butyric aciduria	<b>CACT</b>	Carnitine acylcarnitine translocase	<b>GA-II</b>	Glutaric acidemia Type II	<b>MAL</b>	Malonic acidemia (Malonyl-CoA decarboxylase)
<b>2MBG</b>	2-Methylbutyryl-CoA dehydrogenase	<b>CBL-C,D</b>	Methylmalonic acidemia (Cbl C,D)	<b>GALE</b>	Galactose epimerase	<b>MCKAT</b>	Medium-chain ketoacyl-CoA thiolase
<b>3MGA</b>	3-Methylglutaconic aciduria	<b>CIT-II</b>	Citrullinemia type II	<b>GALK</b>	Galactokinase	<b>MET</b>	Hypermethioninemia
<b>ARG</b>	Arginemia (Arginase deficiency)	<b>CPT-Ia</b>	Carnitine palmitoyltransferase I	<b>H-PHE</b>	Benign hyperphenylalaninemia	<b>SCAD</b>	Short-chain acyl-CoA dehydrogenase
<b>BIOPT-BS</b>	Defects of biotin cofactor biosynthesis	<b>CPT-II</b>	Carnitine palmitoyltransferase II	<b>IBG</b>	Isobutyryl-CoA dehydrogenase	<b>TYR-II</b>	Tyrosinemia type II
<b>BIOPT-REG</b>	Defects of biotin cofactor regeneration	<b>De-Red</b>	Dienoly-CoA reductase	<b>M/SCHAD</b>	Medium/Short chain L-3-hydroxy acyl-CoA dehydrogenase	<b>TYR-III</b>	Tyrosinemia type III